{"id":27585,"date":"2024-04-10T18:18:40","date_gmt":"2024-04-10T12:48:40","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27585"},"modified":"2024-04-10T18:20:11","modified_gmt":"2024-04-10T12:50:11","slug":"doc1021-phase-i-results","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results","title":{"rendered":"DOC1021 \u2013 Unveiling Hope: Diakonos Oncology&#8217;s Breakthrough in Glioblastoma Treatment: AACR 2024"},"content":{"rendered":"\n<p>Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed.<\/p>\n\n\n\n<p>At AACR 2024, Diakonos Oncology announced promising interim analysis of the Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021) showing substantially increased survival of glioblastoma multiforme (GBM) patients well beyond the expected median overall survival (mOS) of 12.7 months for patients receiving the standard of care (SOC).<\/p>\n\n\n\n<p>Findings from the ongoing analysis show that 12\/16 newly diagnosed GBM patients remain alive with no attributable serious adverse events at an average of 12.9 months of follow-up. The current 12-month overall survival of 88% for unmethylated GBM patients compares favorably to the fifty-three percent&nbsp; 12-month historical survival of unmethylated GBM patients treated with standard of care.<\/p>\n\n\n\n<p>Moreover, Diakonos&#8217; trial has garnered praise for its inclusive trial design. 56% of enrolled patients, who would have likely been excluded from other GBM clinical trials due to factors like pre-treatment progression, subtotal resection status, or advanced age, participated. Despite facing challenging prognoses, these patients experienced a statistically significant improvement in expected overall survival, with an increase of 7.7 months compared to similar patients.<\/p>\n\n\n\n<p>DOC1021 has received Fast Track and Orphan Drug Designations from the US FDA. The company expects to begin Phase II trials of DOC1021 for GBM patients within the next year and is conducting two other clinical development programs in pancreatic cancer and angiosarcoma.<\/p>\n\n\n\n<p>For more information on Glioblastoma Multiforme, refer to DelveInsight\u2019s report:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market\">Glioblastoma Multiforme Market Insight, Epidemiology and Market Forecast -2032<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous system (CNS). Despite advancements in diagnostic approaches and the development of new therapies, the prognosis for glioblastoma patients remains notably poor, with limited improvement observed. At AACR 2024, Diakonos Oncology announced promising interim analysis of the Phase 1 (NCT04552886) open-label [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":27586,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[3057,22035,20587],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-27585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aacr","tag-aacr-2024","tag-aacr-conference","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Diakonos&#039; DOC1021 Phase I Results | AACR 2024<\/title>\n<meta name=\"description\" content=\"At AACR 2024, Diakonos announced promising interim analysis of Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diakonos&#039; DOC1021 Phase I Results | AACR 2024\" \/>\n<meta property=\"og:description\" content=\"At AACR 2024, Diakonos announced promising interim analysis of Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-10T12:48:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-04-10T12:50:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10181831\/doc1021-phase-i-results.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Diakonos' DOC1021 Phase I Results | AACR 2024","description":"At AACR 2024, Diakonos announced promising interim analysis of Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results","og_locale":"en_US","og_type":"article","og_title":"Diakonos' DOC1021 Phase I Results | AACR 2024","og_description":"At AACR 2024, Diakonos announced promising interim analysis of Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021)","og_url":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-04-10T12:48:40+00:00","article_modified_time":"2024-04-10T12:50:11+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10181831\/doc1021-phase-i-results.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results","url":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results","name":"Diakonos' DOC1021 Phase I Results | AACR 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10181831\/doc1021-phase-i-results.png","datePublished":"2024-04-10T12:48:40+00:00","dateModified":"2024-04-10T12:50:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"At AACR 2024, Diakonos announced promising interim analysis of Phase 1 (NCT04552886) open-label trial of its dendritic cell vaccine (DOC1021)","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/doc1021-phase-i-results#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10181831\/doc1021-phase-i-results.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10181831\/doc1021-phase-i-results.png","width":466,"height":284,"caption":"doc1021-phase-i-results"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/10181831\/doc1021-phase-i-results-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AACR<\/span>","<span class=\"advgb-post-tax-term\">AACR 2024<\/span>","<span class=\"advgb-post-tax-term\">AACR Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Apr 10, 2024","modified":"Updated on Apr 10, 2024"},"absolute_dates_time":{"created":"Posted on Apr 10, 2024 6:18 pm","modified":"Updated on Apr 10, 2024 6:20 pm"},"featured_img_caption":"doc1021-phase-i-results","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27585"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27586"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27585"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27585"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}